×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Predicting Drug Off-Target Protein Binding to Hypothesize Mechanisms for Safety Issues
Session Chair(s)
Keith K. Burkhart, MD
Senior Advisor for Medical Toxicology, DARS, OCP, OTS
FDA, United States
A new technology predicts a drug’s binding to protein ligands, potentially identifying off-target actions. Preclinical case studies and a postmarket analysis of drug-induced serotonin syndrome are presented.
Learning Objective : Discuss new technology that predicts off-target drug-protein binding; Describe applications for use throughout a drug’s life cycle; Demonstrate a biological plausibility analysis for serotonin syndrome.
Speaker(s)
Use of In Silico Approach for Safety Assessment of Clinical Candidates: Mitigation and Management for Clinical Drug Positioning
Laszlo A. Urban, DrSc, MD, PhD
Novartis Institutes for BioMedical Research, Inc., United States
Global Head, Preclinical Safety Profiling
Predicting Secondary Pharmacology from Drug Off-Target Networks
Michael J. Keiser, PhD
Seachange Pharmaceuticals Inc, United States
Assistant Professor, UCSF; Founder
Use of In Silico Protein Binding Predictions in Postmarket Safety Signal Analysis and Biological Plausibility
Keith K. Burkhart, MD
FDA, United States
Senior Advisor for Medical Toxicology, DARS, OCP, OTS
Have an account?